BioSpace News Archive

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022.

Lannett Company, Inc. announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes.

NovaBay® Pharmaceuticals, Inc. announces the newest addition to the DERMAdoctor® Picture Porefect® collection: 15% Niacinamide Pore Minimizing Serum.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today will present new data across its protein degradation platform at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR (“ENA”) annual meeting to be held October 26-28, 2022.

TransCode Therapeutics, Inc., an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

XORTX Therapeutics Inc. is pleased to announce receipt of a further no objection letter from Health Canada regarding the Company’s ongoing XRX-OXY101 clinical bridging pharmacokinetics study.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the start of enrollment of the first patient cohort (n=4) in its Intermediate Size Patient Population Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis (SPMS) patients.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced preclinical data characterizing its fourth-generation epidermal growth factor receptor (EGFR) inhibitor, THE-349, will be detailed in a live poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (ENA).